View in EDS HTML Full Text PDF Full Text

ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.

Saved in:
Bibliographic Details
Title: ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
Authors: Munshi M; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Liu X; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Kofides A; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Tsakmaklis N; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Hunter ZR; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Guerrera ML; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Canning A; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Gustine JN; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Boston University Medical Center, Boston, Massachusetts, USA., Liu S; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Hatcher JM; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Chen J; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Boston University Medical Center, Boston, Massachusetts, USA., Meid K; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Sarosiek S; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Flynn CA; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Branagan AR; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., von Keudell G; Harvard Medical School, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Palomba LM; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Castillo JJ; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Yang G; Dana Farber Cancer Institute, Boston, Massachusetts, USA., Treon SP; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
Source: British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1866-1872. Date of Electronic Publication: 2024 Sep 18.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39295138
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Munshi+M%22">Munshi M</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Liu+X%22">Liu X</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Kofides+A%22">Kofides A</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Tsakmaklis+N%22">Tsakmaklis N</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hunter+ZR%22">Hunter ZR</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Guerrera+ML%22">Guerrera ML</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Canning+A%22">Canning A</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Gustine+JN%22">Gustine JN</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Boston University Medical Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Liu+S%22">Liu S</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Hatcher+JM%22">Hatcher JM</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Boston University Medical Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Meid+K%22">Meid K</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Sarosiek+S%22">Sarosiek S</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Flynn+CA%22">Flynn CA</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Branagan+AR%22">Branagan AR</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22von+Keudell+G%22">von Keudell G</searchLink>; Harvard Medical School, Boston, Massachusetts, USA.; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Palomba+LM%22">Palomba LM</searchLink>; Memorial Sloan Kettering Cancer Center, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22Castillo+JJ%22">Castillo JJ</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Yang+G%22">Yang G</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Treon+SP%22">Treon SP</searchLink>; Dana Farber Cancer Institute, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220372544%22">British journal of haematology</searchLink> [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1866-1872. <i>Date of Electronic Publication: </i>2024 Sep 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0372544 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1365-2141 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200071048%22">00071048 </searchLink><i>NLM ISO Abbreviation: </i>Br J Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39295138
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/bjh.19756
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1866
    Titles:
      – TitleFull: ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Munshi M
      – PersonEntity:
          Name:
            NameFull: Liu X
      – PersonEntity:
          Name:
            NameFull: Kofides A
      – PersonEntity:
          Name:
            NameFull: Tsakmaklis N
      – PersonEntity:
          Name:
            NameFull: Hunter ZR
      – PersonEntity:
          Name:
            NameFull: Guerrera ML
      – PersonEntity:
          Name:
            NameFull: Canning A
      – PersonEntity:
          Name:
            NameFull: Gustine JN
      – PersonEntity:
          Name:
            NameFull: Liu S
      – PersonEntity:
          Name:
            NameFull: Hatcher JM
      – PersonEntity:
          Name:
            NameFull: Chen J
      – PersonEntity:
          Name:
            NameFull: Meid K
      – PersonEntity:
          Name:
            NameFull: Sarosiek S
      – PersonEntity:
          Name:
            NameFull: Flynn CA
      – PersonEntity:
          Name:
            NameFull: Branagan AR
      – PersonEntity:
          Name:
            NameFull: von Keudell G
      – PersonEntity:
          Name:
            NameFull: Palomba LM
      – PersonEntity:
          Name:
            NameFull: Castillo JJ
      – PersonEntity:
          Name:
            NameFull: Yang G
      – PersonEntity:
          Name:
            NameFull: Treon SP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1365-2141
          Numbering:
            – Type: volume
              Value: 205
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: British journal of haematology
              Type: main
ResultId 1